Literature DB >> 2082739

[A Japanese family of Nettleship Falls X-linked ocular albinism].

M Hayakawa1, A Kanai, K Kato, A Nakajima, K Takamori.   

Abstract

A family with Nettleship Falls X-linked ocular albinism (NFXOA) was reported. The funduscopic examination revealed that both the male proband case and his maternal male cousin with nystagmus and amblyopia had macular hypoplasia and slightly less pigmented fundus than normal Japanese, and the carrier female (proband's mother) had the characteristic pigmentary mosaicism of the fundus. The slitlamp biomicroscopic examination revealed that the proband case's iris was less pigmented and the carrier female had the normal coloured iris. Translucency was not found in the iris of either the proband case or the carrier female. Hypopigmented maculas were found on the skin of the proband case. Histopathological findings of the cutaneous tissue of both the proband case and the carrier female showed macromelanosomes in the epidermis. The diagnosis of NFXOA is considered to be difficult by ocular clinical signs in the case of Japanese male patients without both characteristic albinotic fundus and the mother's pigmentary mosaicism of the fundus. Macromelanosomes recognized by skin biopsy are helpful for diagnosis.

Entities:  

Mesh:

Year:  1990        PMID: 2082739

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  3 in total

1.  X linked ocular albinism in Japanese patients.

Authors:  T Shiono; M Tsunoda; Y Chida; M Nakazawa; M Tamai
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

2.  Molecular genetic and clinical evaluation of three Chinese families with X-linked ocular albinism.

Authors:  Xuan Zou; Hui Li; Lizhu Yang; Zixi Sun; Zhisheng Yuan; Huajin Li; Ruifang Sui
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

3.  A novel GPR143 mutation in a Chinese family with X‑linked ocular albinism type 1.

Authors:  Xuhui Gao; Tiecheng Liu; Xuan Cheng; Aiai Dai; Wei Liu; Runpu Li; Maonian Zhang
Journal:  Mol Med Rep       Date:  2019-11-12       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.